drugset / Trial / NCT03001323
Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
RandomizedParallel-groupOpen-labelTreatment
Summary
Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will randomize participants to control and intervention group. Control group will receive Lantus/Levemir and intervention group will receive degludec. The investigators will call participants monthly and see them in the clinic every three months.The investigators will follow them for 1 year and evaluate if there will be a difference in rate of DKA in between these two groups.
Timeline
- Start
- 2017-01
- Primary completion
- 2019-01-20
- Completion
- 2020-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degludec | Protein / enzyme biologic | 0.2 iu/kg | — |
| Subject | Degludec | Protein / enzyme biologic | 0.3 iu/kg | — |
| Comparator | insulin detemir | Protein / enzyme biologic | 0.2 iu/kg | — |
| Comparator | insulin detemir | Protein / enzyme biologic | 0.3 iu/kg | — |
| Comparator | insulin glargine | Protein / enzyme biologic | 0.2 iu/kg | — |
| Comparator | insulin glargine | Protein / enzyme biologic | 0.3 iu/kg | — |